Press release
Nutrition & Care
November 2, 2017

Evonik and Lilly renew long-term supply agreement

  • Renewed long-term supply agreement for key active pharmaceutical ingredients (API) and intermediates for both human and veterinary products
  • Much of the supply will come from Tippecanoe Laboratories, an Evonik site in Indiana (USA), which was acquired from Lilly in 2010 and which has been producing for Lilly ever since
  • Evonik’s Tippecanoe facility is now one of the largest pharmaceutical CDMO in the world, developing and producing complex pharma actives and intermediates for more than 20 customers

Evonik Industries and Eli Lilly and Company (Lilly) today announced the renewal of a long-term agreement under which Evonik will supply active pharmaceutical ingredients (APIs) and intermediates for use in key Lilly human and veterinary drug products.

Dr. Jean-Luc Herbeaux, Head of Evonik’s Health Care Business Line, explained: “The renewal of this supply agreement is clear evidence of the continued excellent collaboration between Evonik and Lilly. Evonik thanks Lilly for their great vision in transferring a well-maintained asset to Evonik in 2010 – and for their confidence in Evonik and our Tippecanoe facility as a reliable and dependable CDMO, both now, and in the future.”
Evonik acquired the Tippecanoe site in Lafayette in the U.S. State of Indiana from Lilly, a global healthcare leader, in January 2010. The facility has been operating as a contract development and manufacturing organization (CDMO) for the pharmaceutical industry since then. It now proudly serves more than 20 Evonik customers including Lilly. In addition to becoming a core element of Evonik’s international contract manufacturing business, the facility is one of the world’s largest CDMO with 170 cubic meters of High Potency APIs (HPAPIs) capacity and a total of 860 cubic meters of cGMP manufacturing.
The Lafayette site employs approximately 600 people, and leverages both the onsite and global expertise of Evonik’s Health Care Business to support its pharmaceutical customers for the reliable scale-up in production of complex molecules to meet clinical and commercial demand.

Evonik’s Health Care Business Line serves as a best-in-class strategic partner to the pharmaceutical, medical device and food ingredients industry. The broad product portfolio, deep technical know-how and advanced global capabilities create value by helping our customers reduce risk, enhance quality, improve efficiencies and differentiate their brands. The product and service portfolio includes API contract manufacturing, pharmaceutical excipients, advanced food ingredients, amino acids, cell culture ingredients as well as oral and parenteral drug delivery technologies.

About Evonik
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2016, the enterprise generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.

About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,500 employees, and generated sales of around
€4.3 billion in 2016.

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.